| Bioactivity | Leramilimab is a lymphocyte-activation gene 3 (LAG-3) inhibitor, a monoclonal antibody (mAb). Leramilimab can block the LAG-3-mediated inhibitory signal given to tumor infiltrating T cells. Leramilimab shows antitumor activity and can be used in solid tumor research[1]. |
| Name | Leramilimab |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schöffski P, et al. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022 Feb;10(2):e003776. |